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Abstract
Background: Repaglinide is an efficient anti-diabetic drug which is prescribed widely as multi-dosage oral daily
regimens. Due to the low compliance inherent to each multi-dosage regimen, development of prolonged-release
formulations could enhance the overall drug efficacy in patient populations.
Methods: Repaglinide-loaded solid lipid nanoparticles (SLNs) were developed and characterized in vitro.
Various surfactants were used in this study during the nanocarrier preparation procedure and their
corresponding effects on some physicochemical properties of SLNs such as size, zeta potential; drug
loading parameters and drug release profiles was investigated. Stearic acid and glyceryl mono stearate
(GMS) were used as lipid phase and phosphatidylcholin, Tween80, Pluronic F127, poly vinyl alcohol (PVA)
and polyvinyl pyrrolidone (PVP) were used as surfactant/stabilizer.
Results: The results showed some variations between formulations; where the Tween80-based SLNs showed
smallest size, the phosphatidylcholin-based SLNs indicated most prolonged drug release time and the highest
loading capacity. SEM images of these formulations showed morphological variations and also confirmed the
nanoscale size of these particles. The FTIR and DSC results demonstrated no interaction between drug and
excipients. The invitro release profiles of different formulations were studied and observed slow release of
drug from all formulations. However significant differences were found among them in terms of their initial burst
release as well as the whole drug release profile. From fitting these data to various statistical models, the Peppas model
was proposed as the best model to describe the statistical indices and, therefore, mechanism of drug release.
Conclusion: The results of this study confirmed the effect of surfactant type on SLNs physicochemical properties such
as morphological features, loading parameters, particle sizes and drug release kinetic. With respect to the outcome
data, the mixture of phosphatidylcholin/Pluronic F127 was selected as the best surfactant/stabilizer to coat the lipid
core comprising stearic acid and GMS.
Introduction
Diabetes mellitus is a wide spread chronic disease
with serious life-threatening effects on different parts/
functions throughout the body. The majority of dia-
betic patients are found to be type ІІ diabetes melli-
tus, i.e., (non-insulin-dependent). To manage this type
of diabetes, different classes of oral anti-diabetic drugs
are used routinely in the market [1]. Repaglinide, a
drug in the class of meglitinides, is a new anti-
diabetic agent which approved by FDA as an oral
hypoglycemic drug in 1998. It reduces the fasting glu-
cose concentration by stimulating the release of insu-
lin from pancreatic beta cells. Repaglinide differs from
other anti-diabetic drugs in its structure, binding pro-
file, duration of action and mode of excretion. It is
practically insoluble in water, while capable of being
rapidly absorbed from GI tract after oral administra-
tion: a typical behavior in class II Biopharmaceutical
Classification System (BCS II) drugs. Repaglinide under-
goes extensive first pass metabolism in liver which, col-
lectively, results in poor oral bioavailability of the drug
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(56 %). It has a high plasma protein binding (more than
98 %) and its half-life in systemic blood circulation is
about 1 h. Repaglinide causes hypoglycemia following oral
administration, although the extent of this feature is less
than the sulphonylureas [2]. These properties have pro-
posed the drug as a good candidate for sustain oral deliv-
ery formulations. In this way, many attempts have been
made as application of different carriers such as liquisolid
compacts [3], gastroretentive floating delivery system [4]
and different polymeric nanoparticles [5, 6].
In the recent decades, solid lipid nanoparticles (SLNs)
have attracted many attentions as nanotechnology-based
drug delivery systems. Their potential advantages such as
the possibility of controlled drug release and targeting,
feasible incorporation of lipophilic as well as hydrophilic
drugs, remarkable biocompatibility and low biotoxicity,
capability of avoiding organic solvents in production cycle
and ease of scale up, have provoked many research pro-
jects exploiting the possible use of these nanostructures in
drug delivery. Oral administration of SLNs can potentially
increase the lymphatic transport of drugs, thereby causing
decreased first pass hepatic metabolism and increased oral
bioavailability of the drug [7].
The two main ingredients of SLN-based formulations
are lipid and surfactant/stabilizer. Surfactants reduce the
interfacial tension between the hydrophobic surface of
lipid core and the aqueous environment and, therefore,
stabilize the SLNs structure. The effect of surfactant on
the properties of SLNs has been investigated and de-
scribed in several studies. Drug-independent properties
of SLNs such as particle size, stability and zeta potential
were studied by majority of these researches [8–20] and,
to the best of our knowledge, drug-dependent properties
such as drug incorporation and drug release have not
yet been evaluated as a function of surfactant/stabilizer
composition [12, 18]. Such study will potentially help to
develop efficient carriers to deliver drug by SLNs. In
addition it may shed a light on the mechanism(s) by
which the physicochemical features of a drug may inter-
act with the stabilizer in formation of a drug-loaded
SLN. So in this study it was tried to investigate the ef-
fects of different surfactants on some important attri-
butes of a typical BCS II drug like repaglinide to be
formulated as a SLN-loaded nanopharmaceutical.
Materials and methods
Materials
Repaglinide was a gift from Alborz Darou Pharmaceuti-
cals, (Qazvin, Iran); pluronic F127 was purchased from
Sigma, USA. Stearic acid (Art No. 8.00673.1000, Merck,
Germany), glyceryl mono stearate (GMS, MYVEROL™,
KERRY, Denmark), phosphatidylcholin (Art No. E80-103,
Lipoid, USA), tween80 (Art No. 601809, Titrachem, Iran),
poly vinyl pyrrolidone (PVP; 30 KDa, Rahavard Tamin,
Iran) and poly vinyl alcohol (PVA; 145 KDa, Art No.
1.41353.1000, Merck, Germany) were purchased and ap-
plied. Other ingredients and solvents were from HPLC or
chemical laboratory purity grades, as needed, and were
purchased locally.
Preparation of SLNs
SLNs were prepared by a modified solvent diffusion
method, where ethanolic phase containing 150 mg ste-
aric acid, 50 mg GMS and 50 mg repaglinide was dif-
fused in aqueous phase under magnetic stirring
condition (1000 g) at 50 °C with an addition rate of
1 ml/min and, then, the resulting dispersion was
allowed cooling until the room temperature. Surfac-
tants were added to alcoholic or aqueous phases ac-
cording to their solubility. After formation, SLNs were
centrifuged at 50,000 g and lyophilized. Phosphatidyl-
cholin (100 mg), poly vinyl pyrrolidone (PVP) (1 %),
Tween 80 (1 %), pluronicF127 (100 mg), poly vinyl al-
cohol (PVA) and a mixture of phosphatidylcholin/
Tween80 (100 mg/ 1 %) and phosphatidylcholin/pluro-
nicF127 (100 mg/100 mg) were used as stabilizer dur-
ing the preparation procedure.
Particle size and zeta potential analysis
Particle size and zeta potential distribution of the prepared
SLNs population were determined based on dynamic light
scattering (DLS) technique using a laser scattering particle
size/zeta analyzer (Malvern, model Nano ZS, UK). For
particle size analysis, SLNs were diluted in water until
their refractive index (RI) became to 1.4.
Repaglinide assay
High performance liquid chromatography (HPLC) ana-
lysis was applied for determination of repaglinide con-
centrations in samples from drug loading or in vitro
drug release studies. A HPLC system (Waters, model
1515, USA) was equipped with a UV C18 reverse phased
column (MZ analytical, 250*4.6 mm, Mainz, Germany)
and the mobile phase consisted of acetonitrile: phos-
phate buffer, 10 mM (pH = 2.5) at a ratio of 4:1. Chro-
matography was performed at flow rate of 1 ml/min at
room temperature and the samples absorbance was de-
termined at 245 nm by diode array detector (Waters,
dual absorbances, model 2487, USA).
Determination of drug loading and entrapment efficiency
For this purpose, an accurately weighed amount of
freeze dried of repaglinide-loaded SLNs was dissolved in
ethanol and the quantity of the drug was determined
spectrophotometrically at wavelength of 245 nm. The
drug loading efficiency (DLE) was computed as below:
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Drug loading Efficiency ¼ amount of drug  100
total weight of SLN
To calculate the entrapment efficiency (EE), the SLNs
dispersion were centrifuged at 50,000 g for 45 min and,
then, the supernatant phase was decanted and the
amount of drug in this phase was determined by ultra-
violet spectroscopy at 245 nm. The entrapment effi-
ciency was computed by the equation:
Entrapment efficiency ¼ amount of drug  100
amount of drug used in formulation
Morphology studies by scanning electron microscopy
The size, shape and morphological properties of the pre-
pared nanocarriers were studied by scanning electron
microscopy (SEM). Lyophilized nanoparticles were
coated by gold and at acceleration voltage of 7 kV were
observed by SEM (MIRA TESCAN, Czech Republic).
Fourier transform infrared (FTIR) spectroscopy
The freeze dried samples were homogenously mixed
with potassium bromide and the mixture was then com-
pressed into discs by a hydraulic compressor through
applying pressure of about 10 tones in 2 min. The discs
were placed in infrared light pass and the infrared
spectrum was recorded in region of 400–4000 cm
−1using a FTIR spectroscope (Bruker, Tensor 27,
Germany).
Differential scanning calorimetry
Differential scanning calorimetry (DSC) was carried out
on the lyophilized samples of the nanocarriers using a
differential scanning calorimeter (Mettler-Toledo Inc.,
STARe system, US). 2 mg of accurately weighed lyophi-
lized samples were placed on the aluminum pan and
sealed. An empty aluminum pan was used as standard.
Both pans were heated from 25 °C to 300 °C at a scan-
ning rate of 10 °C per minute under nitrogen flow. The
quantity of heat flow was determined as a function of
samples temperature and it was used to study the ther-
mal behaviors of nanoparticles.
In vitro drug release profile study
The in vitro drug release test was carried out thrice
using dialysis bag diffusion technique. Dialysis bags (cut-
off = 12 KDa) were immersed in distilled water for 24 h
before use. 3 ml of SLNs dispersion equivalent to 2 mg
repaglinide was placed into the dialysis bag, sealed by
double-folding on both sides, and immersed in 100 ml
of phosphate buffered saline (PBS) at 37 ° C. The system
was placed on continuous magnetic stirring at 50 rpm.
At predetermined time intervals, 1 ml sample was taken
from receiver phase and the amount of repaglinide was
analyzed by HPLC method as described above. The vol-
ume of release media was kept constant by addition of
rectified volumes of PBS after each sampling stage. The
sink conditions were preserved at whole time of the test
in such a way that the repaglinide concentration in re-
ceiver phase remained less than 15 % of its saturation
concentration in the same medium. Concentration of
samples was determined by HPLC method as mentioned
above and the release profile of each formulation was
plotted graphically as percent drug released against the
time in a bi-numerical mode.
Drug release kinetic estimation
In order to determine the best model to describe the
kinetic parameters of the drug release profiles, the ex-
perimental release data were fitted to multiple statistical
models. The corresponding equations of each model
were given in Table 1. The linear form of each equation
(y = at + b) was fitted to the pure or transformed data
(according to each equation) and the squared correlation
coefficient (r2) between time and y parameter (related to
release data based on each equation) was determined in
each case. The r2 was used as a critical parameter to
evaluate strength of correlation in models and also to
compare each model with others. In addition, the mean
relative error (MRE) was used as another critical param-
eter in order to overcome possible biases of r2 [21].
MRE was calculated as follows:
MRE ¼ M−Cð Þ  100=C
Where C is the experimental data and M is the calcu-
lated release data from the applied model.
Statistical analysis
All experiments and measurements were replicated
thrice. The mean diameter and standard deviations were
calculated by Microsoft Excel 2007. The effect of
Table 1 Applied statistical models to release data of repaglinide
Function Equation
Zero order M0 −M = kt
First order lnM0 − lnM = kt
Higuchi M0 −M = kt
0.5
Peppas M0 −M = kt
n
Hixon-crowell M0
1/3 −M1/3 = kt
Square root M0
1/2 −M1/2 = kt
weibull M0−M ¼ 1−e
− tTd
 β
Linear wagner Z0 − Z = kt
Log wagner Z0 − Z = klnt
M0and M are the remained amounts of the drug in carrier in the time zero and
t respectively. Z is the probit of surface of nanoparticles along time. K is the
equation constant and β is a shape factor of the equation figure
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different surfactants on the release profiles properties
and kinetics were compared using a one-way analysis of
variance using SPSS 16. In this analysis, statistical differ-
ence was significant when p < 0.05.
Results and discussions
Preparation of solid lipid nanoparticles
The solvent diffusion method was applied in the current
study to prepare SLNs. This method is based on the
rapid diffusion of an organic miscible solvent such as
ethanol or acetone in aqueous solution, which, in turn
causes a remarkable change in the dielectric constant
and solubility parameter of the resulting hydro-organic
solvent that eventually leads to the precipitation of the
lipid in the new system. This lipid particulate which con-
stitutes the core body of the SLNs becomes limited to
the nano-sized via using high shear mixing as well as the
presence of stabilizers in the preparation medium [22].
The simplicity and possibility of avoidance of toxic sol-
vents in the SLNs preparation process described earlier
are the main advantages of this method. Ethanol is
highly soluble in water with minimal interfacial tension,
so it diffuses very quickly in aqueous phase thereby
resulting in the precipitating of lipids which in the pres-
ence of a stabilizer leads to the formation of nanoparti-
cles. In this study some modifications were applied on
the characteristics of standard solvent diffusion method,
where addition of ethanolic solution to the aqueous
phase was performed at about 50 °C. In fact it was seen
that if the temperature was upper than the melting point
of the lipids, the smaller and more stable particles were
produced. It may be due to more rapid evaporation of
organic phase (ethanol) which causes lower tendency of
lipid phase to aqueous phase. This property possibly
forms smaller particles. In addition high temperatures
yield more time for surfactants to adsorb on lipid parti-
cles and stabilize them.[8] In preliminary tests through
using experimental design approach, it was determined
that surfactant concentrations affect the production of
SLNs, with their particle size being considered as the re-
sponse. Other conditions such as stirring rate (in a
domain of 500–2000 g), rate of ethanolic phase addition
to aqueous phase and etc., have no considerable effect
on the particle size as response. Hence these conditions
were kept constant. Such approach for comparison of
different surfactants effect has been observed in several
studies [8, 10, 15, 17]. This approach will help to
evaluate the effect of surfactant only and without any
other interactions. The lipids, repaglinide and surfac-
tants (except PVA which dissolves in water phase) were
completely soluble in ethanol. Among the different sur-
factants used, the phosphatidylcholin-based SLNs
showed most opalescence characteristics and the tween
80-based formulations showed least one. The PVP-based
SLNs showed lowest yield of nanoparticle production,
which can be attributed to its low emulsifying capability.
Effect on the particle size and zeta potential of SLNs
The particle size and zeta potential of different formula-
tions are shown in Table 2. It has been showed that par-
ticles with submicron sizes, specially smaller than
400 nm, could improve bioavailability of drugs [23, 24]
and in our study, as indicated, all the SLNs samples
showed submicron sizes in a desirable range (83–326 nm).
So these nanoparticles are favorable in oral drug delivery
systems. However the extent of bioavailability may be
dependent to nanoparticles size and usually it is increased
by decreasing the size [23, 25]. Hence bioavailability meas-
urement is useful to get a more complete perception of re-
sults of this study and it should be investigated later. It
had been observed that low molecular surfactants form
smaller particles [16]. The reason is their ability to cover
interfacial surfaces more quickly than high molecular sur-
factants [10]. The results of this study agreed those obser-
vations, where tween 80, pluronic and lecithin based SLNs
formed smaller particle sizes than PVA and PVP based
SLNs. Schubert et al. reported that at least 10 % lecithin is
necessary to form nanoparticles [18]. However in this
study SLNs formed using lower percents of lecithin. The
presence of a non-ionic hydrophilic surfactant like tween
80 seems to lead to smaller particles while the phospho-
lipid and co-polymer-based stabilizers made intermediate
Table 2 The particle size, zeta potential and loading parameters of different SLNs
Stabilizer(s) used Size (nm) Zeta Potential (mV) Entrapment
Efficiency
(percent)
Loading
Efficiency
(percent)
Phosphatidylcholin 203 ± 7 (−)54 ± 8 85 ± 4 7.1 ± 2
Phosphatidylcholin + tween80 91 ± 4 (−)29 ± 4 35 ± 2 4.7 ± 2
Phosphatidylcholin + Pluronic 169 ± 11 (−)46 ± 9 83 ± 4 5.4 ± 1
Pluronic 210 ± 15 (−)43 ± 8 78 ± 5 6 ± 3
PVP 326 ± 24 (−)27 ± 5 28 ± 2 2.8 ± 1
PVA 265 ± 14 (−)26 ± 7 57 ± 3 4.5 ± 2
Tween 80 83 ± 3 (−)22 ± 3 27 ± 3 3.1 ± 1
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Fig. 1 SEM images of different formulations: a: tween 80, b: tween 80 + phosphatidylcholin, c: phosphatidylcholin, d: PVA, e: PVP, f: pluronic F127,
g: phosphatidylcholin + pluronic F127
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sizes and the poly-vinyl-based stabilizers led to largest par-
ticles among others. The lowest size was observed when a
mixture of tween 80 and phosphatidylcholin was used.
Blending of surfactants can decrease the particle size and
this property was observed in several investigations [12,
16, 18–20, 26, 27]. The results of our study confirm that
theory, while addition of tween 80 to phosphatidylcholin
and pluronic f127 decreases the particle sizes. The zeta
potentials of all formulations were in the negative region,
which related to the negative charge of lipids, however,
the absolute value of this parameter was dependent to the
applied surfactant. This feature of SLNs has been
Fig. 2 FTIR spectrums of a: SLNs-tween80, b: stearic acid, c: SLNs-PVP, d: repaglinide, e: SLNs-pluronic, f: SLNs-PVA, g: SLNs-pluronic/phosphatidylcholin,
h: SLNs-phosphatidylcholin
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confirmed by various studies [19, 20, 26]. Phosphatidyl-
cholin and mixtures containing it, due to its ionic charac-
teristic, showed the highest surface potential. In fact
phosphatidylcholin due to its ionic structure forms an
electric double layer on the surface of nanoparticles and
this layer increases the zeta potential [10]. Nonionic sur-
factants stabilize SLNs through their steric properties [19].
The mixture of ionic surfactant like phosphatidylcholin
and a nonionic surfactant like pluronic f127 forms more
stabilized SLNs [12, 18, 19]. It seems that the molecular
weight, structure and conformation play an important role
on the quantity of zeta potential of SLNs. Presence of rela-
tively high zeta potential value led to more stable nanopar-
ticles and overcomes the tendency of aggregation due to
wander walls attraction forces [10].
Drug loading parameters
The drug loading efficiency and entrapment efficiency of
different formulations have been shown in Table 2. The
majority of the formulations, as shown, had remarkable
drug entrapment efficiency as well as drug loading. The
drug solubility in matrix solvent, miscibility in lipid phase
and the lipid phase polymorphic state have shown to
affect the loading quantity [4, 6, 28, 29]. Repaglinide is
poorly soluble in water [30], so it causes low tendency to
escape from lipid carrier and thus as indicated, generally it
shows high entrapment efficiency. Stearic acid forms lipid
structures with high crystalinity [31]. This polymorphic
state repels the drug from SLN core to its surface and to
the matrix of mixture [28]. GMS was added to lipid phase
to decrease the degree of lipid phase crystalinity and to
A
B
Fig. 3 DSC thermograms of a = stearic acid, b = SLNs
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increase loading capacity. As indicated, the loading pa-
rameters show an increase by ascending the particle size
from the smallest sizes (83 nm, 27 %) until medium sizes
(203 nm, 85 %). More increase in the size of particles
showed a decrease in loading parameters. In some previ-
ous studies, the reverse relation between particle size and
loading parameters has been showed [18]. Lowering the
particle size increases the specific surface area and thus in-
crease drug loading. The latter part of our finding can be
explained by this theory. However since limited number
of surfactants were used by Schubert et al., extension of
this theory in all conditions such as lower particle sizes in
our study, is not possible. Mehnert et al., mentioned mo-
bility of drug after incorporation in SLN through particle
surfaces [16]. It is obvious that the bigger surface leads to
a higher mobility and tendency of drug to escape from the
carrier. So it may be concluded that in smaller particles
like tween 80-based SLNs, the whole particle surface is
larger and drug repulsion is higher. Therefore loading
parameters in these smaller particles are lower relatively.
After evaluation of the size and drug loading param-
eters, the phosphatidylcholin/pluronic-based SLNs
which showed maximum loading efficiency (85 %)
with eligible particle size (203 nm) was selected for
further evaluation.
Morphological characterization of SLNs
SEM images of the nanoparticles prepared using different
stabilizers are shown in Fig. 1. The nanoscale sizes of par-
ticles in all formulations are evident, though the shapes
and assemblies are different among the nanoformulations.
The shapes of all nanoparticles except PVP and PVA-
based SLNs were spherical and in these two cases, the
particles were in rod forms. The surface of phosphatidyl-
cholin and phosphatidylcholin/pluronic-based NPs are
smooth but for others are irregular.
FTIR spectroscopy analysis
FTIR spectra of repaglinide, stearic acid and solid lipid
nanoparticles are shown in Fig. 2.
FTIR of pure repaglinide showed peaks at 3306 cm − 1
(NH stretching), 2938 cm − 1 (CH stretching), and
1684 cm − 1 (C =O stretching). The bands at 1040 cm − 1
and 1209 cm − 1 are related to C–O stretching in pheny-
lalkylether structure. The bands at 1566 cm − 1 and
1638 cm − 1 are due to aromatic C = C and N–H bending
respectively.
The FTIR spectrum of stearic acid showed a strong
peak at 1702 cm − 1 (C =O stretching), 2918 cm − 1
(OH stretching) and 2849 cm − 1 (CH stretching). The
long-chain bond is seen in 720 cm − 1 and the CH2 and
CH3 bands are seen in around 1550 cm − 1 and
1300 cm − 1 respectively.
The FTIR spectrum of SLNs shows approximately all
absorbances of stearic acid with some minor displace-
ments for 2918 cm − 1 (OH stretching) and 2849 cm − 1
(CH stretching) which is related to inter-molecular forces
and re-arrangement of molecules in SLNs structure.
Additional peaks in SLNs spectrum are probably related
to the applied surfactants. Therefore, these data indicate
Fig. 4 Release data of different SLNs formulations
Table 3 Particle size and release profile parameters of different surfactant formulations
Surfactant/stabilizer Tween
80
Tween 80+
phosphatidylcholin
Pluronic F127+
phosphatidylcholin
Phosphatidylcholin Pluronic
F127
PVA PVP
Particle size (nm) 83 91 169 203 210 265 306
Burst release (%) 27.5 17.13 8.4 11.8 11.6 10.5 6.4
Release rate (%/h) 1.49 1.55 1.49 1.63 1.4 1.16 1.12
Max. drug depletion
(%)
86.42 84.14 81.68 72.21 78.44 66.14 46.8
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no formation of chemical bonds between the nanocarrier
and the drug which, in turn, ensures the stability of the
drug main structure during the preparation process.
Differential scanning calorimetry (DSC) analysis
DSC thermograms of stearic acid and SLNs have been
shown in Fig. 3. As shown, the peak related to stearic
acid melting displaced slightly from 60 °C to 57 °C. The
GMS melting point is similar to stearic acid and thus
maybe shows interaction with it in this area. The peak
related to pluronic F127 is seen lower than 50 °C. All
these findings indicate minor displacements of the ingre-
dient peaks which imply new molecular arrangements
rather than the formation new chemical bonds between
ingredients, a finding supported by the FTIR data.
In vitro drug release
The dialysis bag method was used to determine the
release profile of the drug from SLNs. This is an effi-
cient method to study the drug release from nanocar-
riers [32]. The release profiles of the drug from seven
different SLNs have been shown in Fig. 4. There are
clear differences among profiles which have been
described by evaluating key factors of the profiles.
These key factors are: i) the burst release, ii) the re-
lease rate and iii) the maximum drug depletion quan-
tity (MDDQ) (Table 3). The amount of burst release
of the drug (total cumulative of drug released in first
one hour) from different formulations was signifi-
cantly different and accordingly, the formulations can
be classified into three groups of: low burst release
Fig. 5 Correlation between particle size and release parameters; burst release, maximum drug depletion and release rate
Table 4 R-squared from fitting release data of different formulations on various models
Phosphatidylcholin Phosphatidylcholin/pluronic Pluronic PVA PVP Tween Tween/phosphatidylcholin
Zero 0.78 0.88 0.85 0.82 0.72 0.73 0.89
First 0.86 0.96 0.92 0.89 0.77 0.85 0.97
Higuchi 0.93 0.98 0.96 0.94 0.88 0.89 0.97
Peppas 0.99 0.97 0.98 0.98 0.98 0.996 0.98
Hixon-crowell 0.84 0.94 0.9 0.87 0.75 0.81 0.95
Square root 0.83 0.93 0.89 0.86 0.75 0.79 0.94
weibull 0.98 0.99 0.99 0.98 0.9 0.98 0.98
Linear Wagner 0.76 0.86 0.84 0.78 0.63 0.77 0.9
Log Wagner 0.98 0.97 0.98 0.99 0.94 0.98 0.96
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(PVP = 6.4 %, pluronic F127 = 11.6 %, PVA = 10.5 %,
phosphatidylcholin/pluronic F127 = 8.4 %, phosphati-
dylcholin = 11.8 %), medium burst release (phosphati-
dylcholin/tween 80 = 17.13 %) and high burst release
(tween 80 = 27.54 %) (Table 3). The quantity of burst
release has direct relation with the amount of drug
existed on the surface of nanoparticles [16, 28]. So it
can be concluded that the greater the burst release,
greater the drug on the particles surfaces. To explain
these differences in multiple SLNs, it seems they re-
lated to variations in particle sizes since in constant
mass of nanoparticles, the smaller ones contain
greater particle surfaces and in our study the smaller
SLNs showed greater burst release.
The second specification of release profiles is the rate
of release. For this purpose, the rate of drug release from
the starting point of the ascending part of the profile to
reach the plateau was calculated. As it was shown in
Table 3, there is no meaningful difference between these
formulations in terms of the release rate.
The third factor was the maximum drug depletion
quantity (MDDQ). The SLNs due to their condensed
and highly ordered molecular conformation, usually re-
tain a part of the loaded drug inside themselves [28]. As
it is shown in Table 3, the amount of drug retained in
SLNs differs in various formulations significantly.
In order to explore these differences, a correlation
analysis was performed between these parameters and
their corresponding particle sizes. As indicated in Fig. 5,
there is a significant reverse correlation between particle
size and the reverse amount of maximum drug depletion
quantity (r2 = 0.815). This quantity parameter equals to
0.657 and 0.580 for the values of burst release and re-
lease rate, respectively.
In explanation of these correlations, it seems that the
higher particle sizes of PVP-based SLNs make a bigger
total internal lipophilic space for the highly lipophilic
drug to be accommodated which becomes smaller and
smaller with decreasing particle sizes for other formula-
tions. The higher the ratio of the internal spaces-to-
interfaces, the higher the total drug retention in particles
would occur. So the lipid core could detain more drugs
and thus the MDDQ becomes greater. The other two
parameters (burst release and release rate) showed no
significant correlation with particle size, as indicated.
Drug release kinetic study
The results from substitution of the empirical data on
different statistical models are shown in Tables 4 and 5.
As indicated, the r2 and MRE values of the weibull and
logarithmic Wagner models showed most fitness with
experimental data in most formulations. It means that
there are surface and size variations in particles along re-
lease process [33, 34].
In addition the Peppas model showed high fitness with
these data which indicates that the diffusion, erosion or
relaxation processes probably contribute in release
process [35, 36].
To determine the share of each parameter, the re-
lease exponent, n, in Peppas equation was calculated
and due to its number in different formulations
(Table 6), it can be argued that in tween-based and
tween/phosphatidylcholin-based SLNs which n < 0.43,
the mechanism of drug release is fickian diffusion,
but in other formulations where 0.51 < n < 0.54, the
mechanism of release is a combination of fickian dif-
fusion and non-fickian release mechanisms such as
erosion and relaxation [35, 36].
Table 5 The mean relative error (MRE) from empirical data to calculated data from models
Phosphatidylcholin Phosphatidylcholin/pluronic Pluronic PVA PVP Tween Tween/phosphatidylchTolin
Zero 21.11 22.61 27.14 26.36 37.06 13.24 20.75
First 25.97 21.93 20.31 24.31 35.88 15.14 11.9
Higuchi 14.8 11.28 10.64 12.44 23.75 10.72 7.62
Peppas 4.49 8.49 5.03 7.63 5.03 1.53 7.8
Hixon-crowell 26.83 25.88 22.91 24.78 36.24 16.19 15.44
Square root 27.5 27.4 24.03 24.99 36.44 16.69 16.92
Weibull 4.09 5.12 5.55 6.4 16.74 2.13 7.33
Linear Wagner 42.85 41.13 25.52 25.5 36.89 36.96 18.05
Log Wagner 3.9 8.6 8.16 4.62 13.44 3.29 11.81
Table 6 The “n” parameter from peppas equation in different formulations
Phosphatidylcholin Phosphatidylcholin/pluronic Pluronic PVA PVP Tween Tween/phosphatidylcholin
n 0.54 0.52 0.52 0.51 0.52 0.36 0.41
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Conclusion
The results of this study confirmed the effect of surfac-
tant type on SLNs physicochemical properties such as
morphological features, loading parameters, particle
sizes and drug release kinetic. These variations due to
surfactant effect have been noted in previous studies. In
addition, an appropriate mixture of surfactants such as
phosphatidylcholin/pluronic can modify the properties
of repaglinide loaded SLNs so that convert it as a suit-
able candidate for delivery of repaglinide for specific
purposes, e.g., improvement of the drug bioavailability.
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